References
- Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228–37.
- Sudarshan S, Holman DH, Hyer ML, Voelkel Johnson C, Dong JY, Norris JS. In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. Cancer Gene Therapy 2005;12:12–18.
- Norris JS, Bielawska A, Day T, El-Zawahri A, ElOjeimy S, Hannun Y, Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther 2006;13:1045–51.
- Musumarra G, Barresi V, Condorelli DF, Scire S. A bioinformatic approach to the identification of candidate genes for the development of new cancer diagnostics. Biol Chem 2003;384:321–7.
- Seelan RS, Qian C, Yokomizo A, Bostwick DG, Smith DI, Liu W. Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chromosomes Cancer 2000;29:137–46.
- Brunner T, Wasem C, Torgler R, Cima I, Jakob S, Corazza N. Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology. Semin Immunol 2003;15:67–76.
- Houston A, O'Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 2004;4:321–6.
- Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nat Med 1997;3:165–70.
- Zheng SY, Li DC, Zhang ZD, Zhao J, Ge JF. Adenovirus-mediated FasL gene transfer into human gastric carcinoma. World J Gastroenterol 2005;11:3446–50.
- Ambar BB, Frei K, Malipiero U, Morelli AE, Castro MG, Lowenstein PR, Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. Hum Gene Ther 1999;10:1641-8.
- Li X, Liu YH, Zhang YP, Zhang S, Pu X, Gardner TA, Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy. Clin Cancer Res 2007;13(18 Pt 1):463–73.
- Bernier J, Cooper JS. Chemoradiation after surgery for high risk head and neck cancer patients: how strong is the evidence? Oncologist 2005;10:215–24.
- Friesen C, Fulda S, Debatin KM. Cytotoxic drugs and the CD95 pathway. Leukemia 1999;13:1854–8.
- Hyer ML, Sudarshan S, Schwartz DA, Hannun YA, Dong J-Y, Norris JS. Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression. Cancer Gene Ther 2003;10:330–9.
- ElOjeimy S, McKillop JC, El-Zawahry AM, Holman DH, Liu X, Schwartz DA, FasL gene therapy: a new therapeutic modality for head and neck cancer. Cancer Gene Ther 2006;13:739–45.
- O'Connell J, Bennett MW, Nally K, Houston A, O'Sullivan GC, Shanahan F. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict. Ann N Y Acad Sci 2000;910:178–92; discussion 193–5.
- Li W, Zhang C, Chen C, Zhuang G. Correlation between expression of DcR3 on tumor cells and sensitivity to FasL. Cell Mol Immunol 2007;4:455–60.
- Strelow A, Bernardo K, Adam-Klages S, Linke T, Sandhoff K, Krönke M, Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death. J Exp Med 2000;192:601–12.
- Saad AF, Meacham WD, Bai A, Anelli V, Elojeimy S, Mahdy AE, The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther 2007;6:1455–60.
- Elojeimy S, Liu X, McKillop JC, El-Zawahry AM, Holman DH, Cheng JY, Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. Mol Ther 2007;15:1259–63.